John Gebhard, Ph.D., is the senior executive director of the office of technology commercialization at the University of Texas Health Science Center at San Antonio, where he defines the strategy and execution on the development and commercialization of innovative technologies. Gebhardfocuses on ‘win-win’ strategies by creating innovative, sustainable partnerships with private entities to large pharmaceutical companies in order to impact healthcare through improving the patient experience via rapid and efficient deployment of new discoveries. Gebhard has experience in academic, industry and the non-profit sectors. Prior to joining the health science center, he managed a diverse healthcare portfolio at the University of Utah, achieving multiple partnerships. Also, Gebhard served as the strategic program director for the Diabetic Complications program at Juvenile Diabetes Research Foundation International, implementing globally a transformational, academic-industry milestone driven program to deliver new therapeutics to the diabetic patient. Gebhard has more than 14 years of biopharmaceutical industry experience with Inflabloc Pharmaceuticals, where he served as the director and the vice president of R&D in pre-clinical to IND-enabling clinical programs centered on therapeutics in ocular and inflammatory indications. A virologist by training, Gebhard also led efforts in the area of RNA-based medicines and DNA vaccines. Gebhard received his doctorate in cellular, viral and molecular biology at the University of Utah and completed a postdoctoral fellowship in viral pathogenesis at The Scripps Research Institute.